New study published on JMIR Formative Research showcases clinical performance of AccurKardia’s AccurBeat platform for QT/QTc remote monitoring using smartwatch ECG data
NEW YORK, October 11, 2022--(BUSINESS WIRE)--AccurKardia, a software company that provides clinical-grade, device agnostic, automated ECG ("electrocardiogram") analytics, today announced the first study showcasing the clinical value of its AccurBeat platform. AccurBeat is AccurKardia’s platform for analysis of 30-seconds ECGs generated by wearable devices. The full study, conducted in collaboration by HITLAB (Healthcare Innovation & Technology Lab) and SUNY Downstate, can be found at this link from JMIR Publications.
The study used smartwatch ECG (Apple Watch) data to test the clinical comparability of AccurBeat’s computerized algorithms for QT and QTc interval measurement versus the current standard of care. While the work is ongoing, preliminary findings indicate AccurBeat holds great promise for remote measurement of important cardiologic health indicators such as the QT/QTc intervals, which is typically assessed in a doctor’s office using a 12-lead electrocardiograph machine. Abnormal prolongation or shortening of the QT interval can mean increased risk for ventricular arrhythmias and even sudden cardiac death.
"This initial publication regarding AccurBeat serves as the foundation by which AccurKardia can bring live-saving solutions – capable of integrating with readily available consumer devices – to the larger cardiac space allowing for quality care regardless of zip code," said Juan C. Jiménez, CEO of AccurKardia. "We are committed to saving lives and closing the gap of health inequities through accessible, accurate, affordable and easy-to-use technology solutions in the ECG space."
"With this study we continue to pave the way toward enabling continuous monitoring for prevention of cardiac events. A tool like this has the potential for meaningful impact clinically as well as on accessibility," said Sara Chokshi, DrPH, Director of HITLAB Research Practice.
"Measurement of QT and corrected QT (QTc) intervals by a smartwatch coupled with the AccuKardia’s assessment platform represents a major step forward in using wearable technologies to facilitate the diagnosis and management of cardiovascular disease," said Jason M. Lazar, MD, MPH, Vice Dean of Education of SUNY Downstate Health Sciences University and Director of Non-Invasive Cardiology at SUNY Downstate Medical Center. "The ongoing collaboration between AccurKardia, HITLAB AND SUNY Downstate Health Sciences University holds great promise for enhancing access to and eliminating disparities in health care in the future."
AccurKardia is a digital-first and software-only healthcare company focused on enabling a world in which a combination of smart devices, reliable and actionable data, and efficient clinical intervention can together improve medical outcomes and save lives. AccurKardia provides clinical-grade, device-agnostic, API-accessible automated ECG analytics to clinical and consumer-grade ECG devices, as well as telehealth and remote patient monitoring companies. For more information about AccurKardia, please visit: https://www.accurkardia.com/.
HITLAB is a healthcare innovation lab specializing in digital health research, strategy, and education. We help leading organizations ideate, create, and evaluate technology-based solutions to pressing healthcare challenges across the globe. HITLAB works with a wide variety of stakeholders in both the public and private sectors to design and disseminate studies, programs, and products that improve healthcare access and delivery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005187/en/
Media Contact: Kelly Ferraro, River North Communications kelly@rivernorthagency.com (646) 275-7040
Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.
The CDC said BQ.1 and one of its descendants, BQ.1.1, represent "a small but fast-growing subset of the Omicron variant."
It has become pretty much impossible to keep up with all of the latest coronavirus variants, but there's most likely a new wave on the way.
A new subvariant of the omicron variant of the coronavirus is becoming increasingly prevalent in the United States, according to data from the Centers for Disease Control and Prevention (CDC). CDC data shows that the BQ.1 and BQ.1.1 variants each made up 5.7 percent of the total number of cases in the country in the…
Two new offshoots that experts say appear to spread easily were estimated to represent 11.4% of U.S. cases by mid-October, according to the CDC.
A faster pace showed positive outcomes for heart disease, cancer, dementia and death, over and above the total number of daily steps taken
As a new study confirms drinking too much really does make you look older, Lisa Salmon looks into other lifestyle factors that may contribute too
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Ahead of Audacy's We Can Survive concert in support of suicide prevention, the always-candid frontwoman discusses mental health awareness and why she has "always believed in the destruction of taboos."
Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.
The minimum treatment for a snake bite is 10 vials of antivenom and the cost of each vial is in the four digits.
The things to remember about dementia are that it is absolutely horrible for you and everyone around you; it’s a high probability; and when it comes to fighting it or avoiding it you are pretty much on your own. Alzheimer’s disease and related dementias are currently killing 6.5 million people in the United States and devastating the lives of many times that when you count the patients’ friends and family. The National Institutes of Health reckons this number is likely to double in the next four decades.
Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.
Doctors are promoting trans “top surgery” on social media, it has emerged amid concerns about the impact on young people.
Expiration or "best by" dates are confusing and leading to food waste. Here's how to tell if your food is still good or is expired, according to experts.
Health standards are no stranger to change. Eggs got caught in the middle early on in the ongoing debate about what is healthy and what isn't healthy. As science evolves, we learn more about what health standards should be for the majority of the public, and health standards change.
Medicine saves lives, but it can also be abused. Drugs are over prescribed at an alarming rate in the U.S. according to a study that was presented at IDWeek 2018. "We found that nearly half the time, clinicians have either a bad reason for prescribing antibiotics, or don't provide a reason at all," Jeffrey A. Linder, MD, MPH, lead author of the study and chief of the Division of General Internal Medicine and Geriatrics at Northwestern University Feinberg School of Medicine, Chicago. "When you co
Spending time outdoors and drinking more water also had positive effects
It wasn’t so long ago that any COVID variant that hit the U.K. was headed to the U.S. in short order. But now the variant—or swarm of variants—to next plague North America is anyone’s best guess.
Medicare’s open enrollment period arrives predictably each fall, blanketing beneficiaries in advertisements. From Oct. 15 through Dec. 7, the roughly 65 million Medicare beneficiaries can pick a new Medicare Part D drug plan, a new Medicare Advantage plan, or switch from original Medicare into a Medicare Advantage plan or vice versa.